These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
111 related items for PubMed ID: 9658722
1. CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily. Molica S, Vitelli G, Levato D, Crispino G, Dell'Olio M, Dattilo A, Matera R, Gandolfo GM, Musto P. Haematologica; 1998 May; 83(5):398-402. PubMed ID: 9658722 [Abstract] [Full Text] [Related]
2. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Kato K, Chu P, Takahashi S, Hamada H, Kipps TJ. Exp Hematol; 2007 Mar; 35(3):434-42. PubMed ID: 17309824 [Abstract] [Full Text] [Related]
4. Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis. Molica S, Levato D, Dell'Olio M, Matera R, Minervini M, Dattilo A, Carotenuto M, Musto P. Haematologica; 1996 Mar; 81(5):428-33. PubMed ID: 8952156 [Abstract] [Full Text] [Related]
5. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. Molica S, Vitelli G, Mirabelli R, Digiesu G, Giannarelli D, Cuneo A, Ribatti D, Vacca A. Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271 [Abstract] [Full Text] [Related]
8. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Widney D, Gundapp G, Said JW, van der Meijden M, Bonavida B, Demidem A, Trevisan C, Taylor J, Detels R, Martínez-Maza O. Clin Immunol; 1999 Nov; 93(2):114-23. PubMed ID: 10527687 [Abstract] [Full Text] [Related]
9. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Trentin L, Zambello R, Sancetta R, Facco M, Cerutti A, Perin A, Siviero M, Basso U, Bortolin M, Adami F, Agostini C, Semenzato G. Cancer Res; 1997 Nov 01; 57(21):4940-7. PubMed ID: 9354461 [Abstract] [Full Text] [Related]
12. Prognostic value of biological variables in B-cell chronic lymphocytic leukemia. Can we improve upon clinical parameters? Molica S. Haematologica; 1997 Nov 01; 82(6):705-9. PubMed ID: 9499672 [Abstract] [Full Text] [Related]
14. Immunophenotypic characterization of the leukemic B-cells from Iranian patients with chronic lymphocytic leukemia: association between CD38 expression and disease progression. Hojjat Farsangi M, Jeddi-Tehrani M, Razavi SM, Sharifian RA, Shamsian Khoramabadi A, Rabbani H, Shokri F. Iran J Immunol; 2008 Mar 01; 5(1):25-35. PubMed ID: 18319522 [Abstract] [Full Text] [Related]
16. Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination. Rutella S, Rumi C, Puggioni P, Barberi T, Di Mario A, Larocca LM, Leone G. Haematologica; 1999 May 01; 84(5):419-24. PubMed ID: 10329920 [Abstract] [Full Text] [Related]
20. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL. Jabłońska E, Kiersnowska-Rogowska B, Rogowski F, Parfieńczyk A, Puzewska W, Bukin M. Rocz Akad Med Bialymst; 2005 May 01; 50():204-7. PubMed ID: 16358967 [Abstract] [Full Text] [Related] Page: [Next] [New Search]